Search

A Small Animal Imager (SAI) for PET has been designed, built, tested in phantoms, and applied to investigations in mice and rats. The device uses principles based on [gamma]-ray induced scintillation in crossed fiber optic detectors connected to Position Sensitive Photomultiplier Tubes (PSPMT). Each detector consists of an epoxied stack of 28 layers of 135 round 1 mm BCF-10 scintillating plastic fibers. The overlap region forms a 13.5 x 13.5 x 2.8 [cm.sup.3] detector volume. Scintillating light from the fibers is detected by two (X and Y directions) Hamamatsu R-2486 PSPMTs with 16 anode wires in each of two orthogonal directions. A centroid-finding algorithm gives the position of a light cluster on the face (photocathode) of a PSPMT. The accuracy of the reconstruction of an interaction position is essentially independent of light cluster position. This translates to a nearly isotropic photon response for the entire detector. The system has been used to test several 3D image reconstruction algorithms, software modifications, and improvements. The sensitivity (~12.6 cps/kBq at 9 cm inner diameter) and sub-millimeter spatial resolution (better than 1 mm in phantoms) obtained with an iterative algorithm incorporating system modeling make the SAI a relatively inexpensive high performance animal imager. The SAI is currently being used for imaging experiments in mice and rats. Index Terms--Antibodies, arsenic, FDG, image reconstruction, positron emission tomography, small animal imaging.

The development of non-invasive imaging methods for early diagnosis of beta cell associated metabolic diseases, including type 1 and type 2 diabetes (T1D and T2D), has recently drawn interest from the molecular imaging community and clinical investigators. Due to the challenges imposed by the location of the pancreas, the sparsely dispersed beta cell population within the pancreas, and the poor understanding of the pathogenesis of the diseases, clinical diagnosis of beta cell abnormalities is still limited. Current diagnostic methods are invasive, often inaccurate, and usually performed post-onset of the disease. Advances in imaging techniques for probing beta cell mass and function are needed to address this critical health care problem. A variety of imaging techniques have been tested for the assessment of pancreatic beta cell islets. Here we discuss current advances in magnetic resonance imaging (MRI), bioluminescence imaging (BLI), and nuclear imaging for the study of beta cell diseases. Spurred by early successes in nuclear imaging techniques for beta cells, especially positron emission tomography (PET), the need for beta cell specific ligands has expanded. Progress for obtaining such ligands is presented. We report our preliminary efforts of developing such a peptidic ligand for PET imaging of pancreatic beta cells.